 |
||||
 |
|
 |
||
 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|||||||||||||||||
TUESDAY 15 JULY Organiser: |
Dr Sandra Siehler, Novartis, Switzerland |
Chair: |
Dr Sandra Siehler, Novartis, Switzerland |
9:30 |
G-protein-mediated signalling pathways in vascular physiology and pathology |
| Dr Stefan Offermanns, University of Heidelberg, Germany | |
10:00 |
Elevated talk: Isoflavone attenuates vascular contraction through inhibition of |
| Rhoa/Rho-kinase signalling pathway | |
| Prof. In Kyeom Kim, Kyungpook National University School of Medicine, Korea | |
10:15 |
Involvement of G12 proteins in signalling processes impacting oncogenesis and metastasis |
| Dr Juhi Juneja, Duke University Medical Center, USA | |
10:45 |
Coffee break |
11:15 |
Regulation of RhoGEF Proteins by Galpha12/13-Coupled Receptors, and Disease-Related Context |
| Dr Sandra Siehler, Novartis, Switzerland | |
11:45 |
Elevated talk: Sphingosine-1-phosphate signalling in rat bladder smooth muscle cells |
| Mr Pieter B. van Loenen, Academic Medical Center, The Netherlands | |
12:00 |
Genetic screens for serotonin signalling mutants reveal competing G-proteins acting to |
| regulate synaptic vesicle priming | |
| Dr Stephen J Nurrish, University College, UK | |
12:30 |
End of symposium |
Organisers:
|
Prof. Christopher Fowler, Umeå University, Sweden |
| Prof. Roger Pertwee, University of Aberdeen, UK | |
Chairs:
|
Prof. Christopher Fowler, Umeå University, Sweden |
| Prof. Roger Pertwee, University of Aberdeen, UK | |
9:30 |
Introduction to the Pharmacology of the Endocannabinoid System |
| Prof. Roger Pertwee, University of Aberdeen, UK | |
9:50 |
Molecular Bases of the Therapeutic use of Antagonists of Endocannabinoid |
| Action Against Metabolic Disorders | |
| Prof. Vincenzo Di Marzo, National Research Council, Italy | |
10:20 |
The Endocannabinoid System as a Target for the Treatment of Motor Dysfunction |
| Prof. Javier Fernandez-Ruiz, Universidad Complutense, Spain | |
10:50 |
Coffee break |
11:10 |
Elevated talk: Role of endocannabinoids in retrograde synaptic signaling in the human cerebral |
| cortex | |
| Prof. Bela Szabo, Albert Ludwig University, Germany | |
11:25 |
Elevated talk: Inhibitors of endocannabinoid hydrolases and cyclooxygenases modulate |
| mesenteric relaxation to anandamide but not 2-arachidonoylglycerol in spontaneously | |
| hypertensive rats | |
| Dr Vanessa Ho, University of Nottingham Medical School, UK | |
11:40 |
Targeting peripheral cannabinoid 1 (CB1) receptor for chronic pain |
| Dr Susan Boyce, Organon Research, The Netherlands | |
12:10 |
Inhibition of Endocannabinoid Metabolism and Dual-action COX/FAAH Inhibitors as a |
| Strategy for the Treatment of Pain | |
| Professor Christopher Fowler, Umeå University, Sweden | |
12:30 |
End of symposium |
Organisers: |
Professor Herman Meurs, University of Groningen, The Netherlands |
| Professor Johan Zaagsma, University of Groningen, The Netherlands | |
Chairs: |
Professor Herman Meurs, University of Groningen, The Netherlands |
| Professor Johan Zaagsma, University of Groningen, The Netherlands | |
9:30 |
Recent Advances in L-Arginine Metabolism |
| Professor Sidney M Morris Jr, University of Pittsburgh, USA | |
10:00 |
Elevated talk: The effect PI3K inhibition on IL-13 –induced arginase I expression in mice |
| tracheal segments | |
| Mrs Hanan Farghaly, Bath University, UK | |
10:15 |
Regulation of Cationic Amino Acid Transport |
| Professor Ellen I Closs, Johannes Gutenberg University, Germany | |
10:45 |
Coffee break |
11:15 |
Role of Arginase in the Immune System |
| Dr Markus Munder, University of Heidelberg, Germany | |
11:45 |
Elevated talk: Regulation of inducible nitric oxide synthase expression by levo- and |
| dextrosimendan | |
| Dr Riku Korhonen, University of Tampere, Finland | |
12:00 |
Arginase: A Novel Ney Enzyme in Asthma |
| Dr Harm Maarsingh, University of Groningen, The Netherlands | |
12:30 |
End of symposium |
Organiser: |
Prof George Karakiulakis, Aristotle University of Thessaloniki, Greece |
Chair: |
Prof George Karakiulakis, Aristotle University of Thessaloniki, Greece |
9:30 |
Modifying the Wnt System as a Therapeutic Approach for Pulmonary Fibrosis |
| Dr Oliver Eickelberg, University of Giessen, Germany | |
9:55 |
Novel Therapeutic Targets in Pulmonary Arterial Hypertension |
| Dr Nicholas W. Morrell, University of Cambridge, UK | |
10:20 |
Elevated talk: A comparison between the incidences of respiratory distress syndrome in |
| preterm infants who were born within 24 hours of dexamethasone being administered to | |
| the mother versus those mothers without | |
| Dr Maryam Kashanian, Iran University of Medical Science | |
10:35 |
Elevated talk: Human respiratory epithelial models for pulmonary drug delivery and |
| toxicity studies | |
| Dr Helena Eixarch, Across Barriers GmbH | |
10:50 |
Coffee break |
11:15 |
The ‘sweet and bitter’ involvement of Glycosaminoglycans in Lung Diseases |
| Dr Eleni Papakonstantinou, Aristotle University of Thessaloniki, Greece | |
11:40 |
The Role of the Smooth Muscle Cell in Airway Remodelling in Asthma |
| Dr Michael Roth, University of Sydney, Australia | |
12:05 |
Role of activins in lung pathopysiology |
| Dr Pashalis Sideras, Academy of Athens, Greece | |
12:30 |
End of symposium |
Organiser: |
Finn Olav Levy, University of Oslo, Norway |
Chairs: |
Professor Jan-Bjørn Osnes, University of Oslo, Norway |
| ProfessorFinn Olav Levy, University of Oslo, Norway | |
9:30 |
Receptor polymorphisms determine the kinetics of ß–adrenergic receptor |
| Stefan Engelhardt, University of Wuerzburg, Germany | |
10:00 |
Elevated talk: Dual critical role of angiotensin AT-1 and serotonin 5-HT2B receptors in |
| non-cardiomyocytes for beta-adrenergic agonist induced pathological left-ventricular | |
| hypertrophy | |
| Dr Fabrice Jaffre, University of Rochester, USA | |
10:15 |
Beta-1 and beta-2 adrenoceptor polymorphisms and cardiovascular diseases |
| Kirsten Leineweber, Bayer Health Care AG, Germany | |
10:45 |
Coffee break |
11:15 |
Regulation of the failing cardiac ventricle through 5-HT2A and 5-HT4 receptors: mechanisms |
| and possible therapeutic consequences | |
| Finn Olav Levy, University of Oslo, Norway | |
11:45 |
Elevated talk: Phosphodiesterases regulating the negative inotropic response of C-type |
| natriuretic peptide in heart failure | |
| Mrs Lise Román Moltzau , University of Oslo, Norway | |
12:00 |
Targeting myocardial alpha1–adrenoceptors to treat heart failure |
| Paul C. Simpson, San Francisco VA Medical Centre, USA | |
12:30 |
End of symposium |
